TLPH: Talphera, Inc.
About
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Current Value
$0.681 Year Return
Current Value
$0.681 Year Return
Key Details
Market Cap
$11.91M
P/E Ratio
-1.03
1Y Stock Return
9.27%
1Y Revenue Growth
-54.82%
Dividend Yield
0.00%
Price to Book
1.2
Strategies that include TLPH
Stock's related to TLPH
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TEM | 30.58% | $8.26B | 0.00% | 0.00% |
| OPRX | 26.28% | $82.71M | -53.90% | 0.00% |
| ARQT | 23.89% | $1.20B | +444.68% | 0.00% |
| RBRK | 23.06% | $8.92B | +53.50% | 0.00% |
| BIDU | 22.02% | $23.84B | -32.04% | 0.00% |
| NVCR | 21.89% | $1.85B | +43.37% | 0.00% |
| RDY | 21.78% | $11.67B | +3.38% | 3.33% |
| CALX | 21.36% | $2.13B | -15.30% | 0.00% |
| ATRO | 20.74% | $604.40M | +11.37% | 0.00% |
| LOGC | 20.56% | $182.94M | +45.91% | 0.00% |
| GEN | 20.45% | $18.37B | +40.68% | 1.67% |
| PRTA | 19.63% | $777.00M | -55.88% | 0.00% |
| SNCR | 19.30% | $96.79M | +74.10% | 0.00% |
| POOL | 19.24% | $13.87B | +2.27% | 1.27% |
| RCUS | 19.06% | $1.31B | +2.96% | 0.00% |
| NVST | 18.96% | $3.68B | -10.80% | 0.00% |
| TEAM | 18.84% | $66.40B | +40.66% | 0.00% |
| SANA | 18.69% | $524.68M | -44.71% | 0.00% |
| PVH | 18.59% | $5.55B | +15.33% | 0.15% |
| WRAP | 18.47% | $68.82M | -41.18% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VNDA | -<0.01% | $288.04M | +40.74% | 0.00% |
| HVT | -0.02% | $379.52M | -25.02% | 5.34% |
| INFU | 0.02% | $196.48M | -4.05% | 0.00% |
| HL | -0.02% | $3.62B | +22.10% | 0.81% |
| SVC | -0.02% | $453.28M | -61.80% | 22.26% |
| GABC | -0.03% | $1.34B | +54.91% | 2.39% |
| CTO | -0.03% | $589.33M | +18.29% | 7.72% |
| INFN | -0.03% | $1.57B | +57.01% | 0.00% |
| GTY | 0.04% | $1.80B | +12.49% | 5.47% |
| DG | 0.04% | $16.26B | -40.85% | 3.18% |
| VLTO | -0.05% | $26.22B | +45.34% | 0.34% |
| LMT | -0.05% | $128.48B | +20.34% | 2.32% |
| MGRC | 0.05% | $2.93B | +20.02% | 1.58% |
| KMB | 0.05% | $45.70B | +12.03% | 3.52% |
| ARES | 0.05% | $35.33B | +60.83% | 2.02% |
| SPHR | -0.05% | $1.47B | +17.56% | 0.00% |
| MVIS | -0.05% | $212.23M | -60.12% | 0.00% |
| UVSP | -0.05% | $898.01M | +64.47% | 2.71% |
| FENG | 0.06% | $13.53M | +94.49% | 0.00% |
| NXDT | 0.06% | $218.01M | -37.12% | 11.55% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CMTL | -17.83% | $91.22M | -73.99% | 0.00% |
| TDS | -13.83% | $3.73B | +73.14% | 1.36% |
| AIFU | -13.74% | $70.89M | -81.83% | 0.00% |
| COKE | -13.33% | $10.92B | +74.37% | 0.32% |
| IMRN | -12.94% | $10.94M | +6.06% | 0.00% |
| PGR | -12.47% | $154.33B | +62.01% | 0.44% |
| ALL | -11.70% | $53.88B | +49.52% | 1.80% |
| MOH | -11.47% | $16.94B | -18.86% | 0.00% |
| CAH | -11.06% | $29.87B | +16.57% | 1.63% |
| ARLP | -10.73% | $3.57B | +27.36% | 9.97% |
| USM | -10.59% | $5.50B | +45.52% | 0.00% |
| TRUP | -10.59% | $2.23B | +99.73% | 0.00% |
| NMM | -10.15% | $1.55B | +121.75% | 0.39% |
| ELV | -10.04% | $93.60B | -15.91% | 1.58% |
| SAR | -10.03% | - | - | 11.36% |
| META | -9.86% | $1.42T | +64.89% | 0.27% |
| FMX | -9.70% | $18.61B | -30.40% | 4.72% |
| LZB | -9.32% | $1.82B | +37.25% | 1.83% |
| CSR | -9.30% | $1.21B | +34.89% | 4.07% |
| THS | -9.17% | $1.81B | -14.53% | 0.00% |
ETF's related to TLPH
News
Yahoo
Talphera ( NASDAQ:TLPH ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.35m (loss widened by 137% from...
Yahoo
Talphera Inc (TLPH) reports progress in clinical trials and regulatory pathways, while addressing enrollment hurdles and financial needs.
Yahoo
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update.
SeekingAlpha
Talphera, Inc. (NASDAQ:TLPH) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsRaffi Asadorian - CFOVincent Angotti -...
Yahoo
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.
Yahoo
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors. The summit is being held on October 15-17, 2024.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.